Holen Sie sich die Stockscreener-App
1.605
0.47%
0.015
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LXRX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.59
Offen:
$1.59
24-Stunden-Volumen:
1.46M
Relative Volume:
0.52
Marktkapitalisierung:
$680.01M
Einnahmen:
$49.80M
Nettoeinkommen (Verlust:
$-50.34M
KGV:
-11.56
EPS:
-0.1388
Netto-Cashflow:
$-67.85M
1W Leistung:
+5.79%
1M Leistung:
-6.58%
6M Leistung:
+3.06%
1J Leistung:
+281.33%
1-Tages-Spanne:
$1.58
$1.64
1-Wochen-Bereich:
$1.52
$1.705
52-Wochen-Spanne:
$0.36
$1.83
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Firmenname
Lexicon Pharmaceuticals Inc
Sektor
Branche
Telefon
(281) 863-3000
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.605 | 673.65M | 49.80M | -50.34M | -67.85M | -0.1388 |
VRTX
Vertex Pharmaceuticals Inc
|
433.59 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.90 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.75 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.75 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.04 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-03-07 | Eingeleitet | Jefferies | Hold |
| 2022-08-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-01-29 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-18 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-12-11 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2019-11-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-11 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-07-29 | Herabstufung | Stifel | Buy → Hold |
| 2019-03-25 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2018-07-31 | Bestätigt | Stifel | Buy |
| 2018-02-23 | Herabstufung | Needham | Buy → Hold |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2017-03-01 | Bestätigt | Wedbush | Outperform |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-08-05 | Bestätigt | Wedbush | Outperform |
| 2016-08-02 | Eingeleitet | Citigroup | Buy |
| 2016-03-02 | Bestätigt | Wedbush | Outperform |
| 2015-11-09 | Bestätigt | Wedbush | Outperform |
| 2015-09-28 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2015-09-18 | Herabstufung | Gabelli & Co | Hold → Sell |
| 2015-08-10 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten
Lexicon Pharmaceuticals (LXRX) price target increased by 15.07% to 3.43 - MSN
Lexicon Pharmaceuticals, Inc. (LX31.MU) stock price, news, quote and history - Yahoo Finance UK
Lexicon Pharmaceuticals joins Texas Life Sciences Summit to engage industry leaders and drive sector momentum - Traders Union
LXRX Technical Analysis & Stock Price Forecast - Intellectia AI
LXRX SEC FilingsLexicon Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8.7% HigherTime to Buy? - MarketBeat
LXRX stock up as NVO initiates phase I study of partnered obesity drug - MSN
Certain Stock Options of Lexicon Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Lexicon Pharmaceuticals unveils ACC26 trial analysis on BMI and cardiovascular outcomes - Traders Union
Published on: 2026-03-29 16:03:42 - baoquankhu1.vn
Lexicon Pharmaceuticals unveils new SOTA‑P‑CARDIA Chapter 2 data in HFpEF at ACC26 - Traders Union
Lexicon Pharmaceuticals Stock: Pipeline Progress and Financial Strategy in Biopharma Sector - AD HOC NEWS
LXRX Stock Chart | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
ACC meeting features Lexicon Pharmaceuticals clinical research presentations - Traders Union
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug - Yahoo Finance
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo - Bitget
Lexicon brings ACC data showing heart benefits across BMI groups - Stock Titan
Lexicon Pharmaceuticals (LXRX) Receives Reiterated Buy Rating at $6.00 | LXRX Stock News - GuruFocus
Lexicon Pharmaceuticals' (LXRX) Buy Rating Reaffirmed at HC Wainwright - marketbeat.com
Novo Nordisk Begins Study of Lexicon Oral Obesity Drug - wsj.com
Lexicon Pharmaceuticals And Novo Nordisk Announce Initiation Of Phase 1 Study With Oral Obesity Drug Candidate LX9851 - TradingView
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851 - Yahoo Finance
HC Wainwright remains a buy on Lexicon Pharmaceuticals (LXRX) - MSN
Published on: 2026-03-22 17:56:17 - baoquankhu1.vn
LXRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
H.C. Wainwright Remains a Buy on Lexicon Pharmaceuticals (LXRX) - Insider Monkey
Lexicon Pharmaceuticals advances chronic pain treatment options with focus on non opioid innovation - Traders Union
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript - MSN
Lexicon Pharma spikes after insider buy - MSN
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Growth Value: How does Lexicon Pharmaceuticals Inc compare to its peers2026 EndofMonth & Low Drawdown Investment Ideas - baoquankhu1.vn
Dip Buying: How much upside does Lexicon Pharmaceuticals Inc have2026 PreEarnings & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
HC Wainwright raises its price target on Lexicon Pharmaceuticals, Inc. (LXRX) to $6 from $4 and maintains a buy rating - MSN
Lexicon Pharmaceuticals, Inc.Common Stock (NQ: LXRX - The Chronicle-Journal
Lexicon Pharmaceuticals (LXRX) 2025 10-K: pipeline updates, collaborations - Stock Titan
Lexicon Pharmaceuticals (NASDAQ: LXRX) asks holders to double shares, renew equity plans - Stock Titan
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Rapid Micro Biosystems (RPID), Lexicon Pharmaceuticals (LXRX) and Whitehawk Therapeutics (WHWK) - The Globe and Mail
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2025 earnings call transcript - MSN
H.C. Wainwright reiterates Buy on Lexicon Pharmaceuticals stock By Investing.com - Investing.com Canada
H.C. Wainwright Raises its Price Target on Lexicon Pharmaceuticals, Inc. (LXRX) to $6 from $4 and Maintains a Buy Rating - Insider Monkey
Lexicon Pharmaceuticals at Leerink Conference: Strategic Pipeline Focus By Investing.com - Investing.com Canada
LXRX: Late-stage trials and regulatory milestones drive pipeline progress and strategic partnerships - TradingView
Lexicon Pharmaceuticals (LXRX) to Present Key Findings on Sotagl - GuruFocus
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes - The Manila Times
Diabetes drug sotagliflozin cut low-sugar events, across kidney stages - Stock Titan
Citigroup Raises Price Target for Lexicon Pharmaceuticals (LXRX) - GuruFocus
Citigroup Forecasts Strong Price Appreciation for Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock - MarketBeat
Lexicon Pharmaceuticals Signals Leaner Path to Key Milestones - TipRanks
What is HC Wainwright's Estimate for LXRX Q1 Earnings? - MarketBeat
Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lexicon Pharmaceuticals Inc-Aktie (LXRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DEBBANE RAYMOND | Director |
Feb 23 '26 |
Buy |
1.47 |
100,000 |
147,000 |
1,904,186 |
| DEBBANE RAYMOND | Director |
Feb 20 '26 |
Buy |
1.48 |
100,000 |
147,790 |
1,804,186 |
| DEBBANE RAYMOND | Director |
Feb 19 '26 |
Buy |
1.44 |
50,000 |
71,965 |
1,704,186 |
| DEBBANE RAYMOND | Director |
Feb 18 '26 |
Buy |
1.32 |
133,688 |
176,468 |
1,654,186 |
| DEBBANE RAYMOND | Director |
Feb 17 '26 |
Buy |
1.31 |
76,857 |
100,544 |
1,520,498 |
| DEBBANE RAYMOND | Director |
Feb 13 '26 |
Buy |
1.31 |
57,952 |
75,877 |
1,443,641 |
| Invus Global Management, LLC | Director |
Feb 02 '26 |
Buy |
1.30 |
1,538,462 |
2,000,001 |
1,538,462 |
| Swain Judith L | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
85,174 |
| Sullivan Diane E. | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
36,810 |
| SOBECKI CHRISTOPHER J | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
203,865 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):